Prognostic value of inflammation‐immunity‐nutrition score in patients with hepatocellular carcinoma treated with anti‐PD‐1 therapy

BACKGROUND: There are no validated biomarkers that can predict the clinical benefit of immune checkpoint blockers against the programmed cell death protein 1 (PD‐1) treatments in hepatocellular carcinoma (HCC). This study aimed to investigate the prognostic value of inflammation‐immunity‐nutrition s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zilong, Liang, Yuxin, Zhong, Deyuan, Dai, Zonglin, Shang, Jin, Lai, Chunyou, Zou, Haibo, Yao, Yutong, Feng, Tianhang, Huang, Xiaolun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102763/
https://www.ncbi.nlm.nih.gov/pubmed/35312116
http://dx.doi.org/10.1002/jcla.24336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102763/
https://www.ncbi.nlm.nih.gov/pubmed/35312116
http://dx.doi.org/10.1002/jcla.24336

Ejemplares similares